Market Overview

UPDATE: Benchmark Raises PT to $20 on Exact Sciences Corporation Ahead of Top Line Data

Share:
Related EXAS
Stocks That Battle Cancer Were The Best-Performing Biotechs In January
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Benchmark maintained Exact Sciences Corporation (NASDAQ: EXAS) with a Speculative Buy and raised the price target from $17.00 to $20.00.

Benchmnark noted, "Exact's Q4 update affirmed our expectation that pivotal top line colorectal cancer study data should be announced in March or April. These results are expected to support the third and final modular PMA filing seeking approval of a colon cancer and pre-cancer screening test. Based on prior tests demonstrating up to 98% cancer sensitivity, we believe there is a high likelihood this prospective study can demonstrate cancer sensitivity that exceeds the FDA's anticipated 85% threshold for approval."

Exact Sciences Corporation closed at $10.56 on Wednesday.

Latest Ratings for EXAS

DateFirmActionFromTo
Jan 2015Lake Street CapitalInitiates Coverage onBuy
Oct 2014Canaccord GenuityMaintainsBuy
Oct 2014Stephens & Co.DowngradesOverweightEqualweight

View More Analyst Ratings for EXAS
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Analyst Ratings

 

Related Articles (EXAS)

Around the Web, We're Loving...

Get Benzinga's Newsletters